Since PPARγ has a broad range of transcriptional targets, the enhanced molecular response in pioglitazone treated CML patients reported in Rousselot et al. [72] and Yanamandra et al. [73], may not specifically result from changes in LD regulation. This evidence concerns the gene PPARG and chronic myelogenous leukemia, BCR-ABL1 positive.